Form 4: Nurix CSO Sells Shares for Tax Obligations

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the vesting of restricted stock units and subsequent sale of shares to cover tax withholding obligations.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), reported multiple transactions on January 30, 2026.
• These transactions involved the vesting of 11,816 restricted stock units (RSUs) into common stock.
• Concurrently, 4,895 shares were sold in "sell to cover" transactions to satisfy tax withholding obligations.
• The sales occurred at weighted average prices of $16.5826 (for 4,797 shares) and $17.3717 (for 98 shares).
• Following these transactions, Gwenn Hansen directly beneficially owns 83,672 shares of common stock and 46,475 unvested restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves a sale of shares, it's a non-discretionary 'sell to cover' for tax purposes, which is a standard and expected part of RSU vesting for executives. The underlying RSU vesting itself is a positive sign of ongoing executive compensation and retention.

Positives

• The vesting of restricted stock units indicates continued equity compensation for a key executive, aligning interests with shareholders.
• The "sell to cover" mechanism is a standard practice for managing tax liabilities associated with RSU vesting, not a discretionary sale.

Negatives

• A portion of shares were sold, reducing the direct beneficial ownership of the Chief Scientific Officer by 4,895 shares.

Future Outlook

The filing indicates ongoing equity compensation for the Chief Scientific Officer through future RSU vesting schedules, contingent on continued service to Nurix Therapeutics.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and expected practice in the biotechnology industry for executives receiving equity compensation, particularly restricted stock units. This mechanism allows executives to manage tax liabilities without needing to use personal funds, thereby facilitating the retention of key talent through long-term equity incentives. The transactions themselves do not reflect a change in the executive's discretionary investment strategy but rather a procedural aspect of compensation.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of restricted stock units (RSUs) as a significant component of executive compensation, coupled with 'sell to cover' provisions for tax obligations, aligns with standard practices among publicly traded biotechnology and pharmaceutical companies.
• For instance, companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar equity incentive structures to attract and retain scientific and executive talent, where vesting schedules are tied to continued service, and tax obligations are often met through mandated share sales.
• This approach is widely accepted as a fair and efficient method for both employee compensation and tax compliance in the sector.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not a signal of lack of confidence. The underlying RSU grants align executive interests with long-term shareholder value.
• Employees: Reinforces the company's commitment to equity-based compensation for key personnel.

Next Steps

• Continued vesting of remaining restricted stock units for Gwenn Hansen, contingent on continued service to Nurix Therapeutics.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by a key executive to satisfy tax obligations upon RSU vesting. Such non-discretionary sales are a standard part of executive compensation and do not typically signal a change in the executive's outlook on the company or its prospects. The underlying RSU grants represent ongoing equity incentives, which is generally positive for aligning management and shareholder interests. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it reflects expected operational compensation practices rather than a strategic shift or significant new financial data.

Keywords

Nurix Therapeutics, NRIX, Gwenn Hansen, Chief Scientific Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Sell to Cover, Equity Compensation, Beneficial Ownership